Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

NCT01701674 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma

Interventions

DRUG: Ipilimumab
PROCEDURE: Tumor Infiltrating Lymphocytes (TIL)
DRUG: Administration of Lymphodepletion
DRUG: Cyclophosphamide as Part of Lymphodepletion
DRUG: Fludarabine as Part of Lymphodepletion
DRUG: High Dose IL-2
BIOLOGICAL: Adoptive Cell Therapy with TIL

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]
[object Object]